We read with interest the recent report by Shonibare and Lochhead 1 describing a patient with visual confusion who suffered troublesome visual ghosting following primary implantation of a near-infrared (NIR)-transmitting black IOL. Secondary implantation of a NIR-blocking Artisan black IOL abolished the patient's symptoms.
Simultaneously-and independently-we reported an identical experience in a patient with intractable diplopia who required a secondary NIR-blocking Artisan IOL to suppress debilitating visual ghosting. 2 NIR light is assumed imperceptible to humans, yet perception of light is almost universal in patients following NIR-transmitting black IOL implantation. 3 In all, 91% of patients perceived light post-operatively, the remainder had acquired optic neuropathies with impaired long-wavelength spectral sensitivity and consequently could not perceive NIR light. 3 Taken together, these observations suggest that careful and systematic evaluation of both patient factors and black IOL properties are necessary to identify the optimal primary black IOL implant pre-operatively in each patient to minimize the risk of treatment failure.
First, patient factors should be considered including the necessity of posterior segment monitoring, need for absolute light occlusion, scotopic pupil size, lens status, and optic nerve pathology (Table 1) . Second, the properties of each black IOL, including optimum surgical configuration, occlusive optic size, and utility in primary and secondary IOL implantation must then be considered (Table 2) . Black intraocular lenses are variably occlusive to NIR light and may be usefully categorized by this property. 4 High levels of post-operative satisfaction have been reported with NIR-transmitting black IOL implantation, 5 although emerging reports of treatment failure do advise some caution. [1] [2] [3] Predicting this risk pre-operatively is critical to the long-term efficacy of surgical intervention. Design of a NIR-transmitting black contact lens would permit a therapeutic trial to determine pre-operative NIR light sensitivity where uncertainty exists. Primary implantation of a NIRblocking IOL would be advised if troublesome ghosting occurred.
SLO/OCT posterior segment imaging remains a distinct clinical advantage in patients with NIR-transmitting black IOLs and may improve long-term safety. However, informed consent in this context must raise the possibility of treatment failure and need for secondary NIR-blocking IOL implantation in this patient group. Implants are categorized by NIR-transmitting properties. The compatibility with posterior segment SLO/OCT imaging, risk of unwanted NIR light perception, compatibility with primary black-on-clear polypseudophakia surgical configuration, anatomical location for primary black IOL implantation, and utility for secondary black IOL implantation are specified for each implant.
CORRESPONDENCE
a Caution advised as foldable black IOL may degrade over time in a piggyback surgical configuration with a PMMA IOL.
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The authors declare no conflict of interest. Cataract extraction and intraocular lens (IOL) insertion is the most commonly performed operation on elderly people in Europe. 1 In February 2013, HOYA (HOYA Corporation, Singapore, Singapore) recalled certain IOLs due to concerns with postoperative inflammation. 2 We describe the first case of sterile postoperative endophthalmitis secondary to a HOYA IOL, requiring explantation.
Case report
A 44-year-old man presented for left cataract assessment, with a known history of Fuchs' heterochromic cyclitis. On examination, visual acuity was 6/18 with stellate keratic precipitates and cells in the anterior chamber. He had posterior subcapsular lens opacification and a normal fundus.
He underwent phacoemulsification with a þ 21.5-D HOYA iSert 251 IOL (HOYA Corporation) inserted. He missed his follow-up appointment and presented 3 weeks postoperatively complaining of pain, having prematurely stopped his postoperative maxitrol drops. His visual acuity was hand movements with corneal edema, anterior chamber inflammation and a 1-mm hypopyon. B-scan revealed vitritis and a flat retina.
The patient commenced hourly dexamethasone 0.1%, cyclopentolate 1% three times a day, chloramphenicol 0.5% four times a day, and 400 mg oral moxifloxacin once a day. An aqueous and vitreous biopsy with intravitreal antibiotic (vancomycin and ceftazadine) was performed. No organisms were grown on subsequent culture of the biopsy.
As the intraocular inflammation persisted, oral steroid (40 mg prednisolone daily) was started; however, this failed to control the inflammation. Six weeks postoperatively, in light of HOYA's recall, the lens was explanted, with concurrent intravitreal triamcinolone (0.1 ml) and intracameral cefuroxime (1 ml). The explanted IOL was returned to HOYA for analysis, the results of which are pending. The inflammation improved the following day, with complete resolution in 1 month. Three months later, following posterior chamber Alcon AcrySof IOL (Alcon, Inc., Fort Worth, TX, USA) insertion his visual acuity was 6/6. Comment HOYA voluntarily withdrew a cohort of IOLs (including HOYA iSert 251 lenses) after review of their manufacturing process revealed residual metallic particles on these IOLs. 2 The cause was identified, rectified, and HOYA is now manufacturing these IOLs with appropriate regulatory approval. Our patient's intraocular lens was identified within this cohort.
On the basis of persistent inflammation despite intensive topical and oral steroids, and its swift resolution following explantation of the IOL, we felt the inflammation was due to the IOL rather than a postoperative episode of Fuchs' heterochromic cyclitisrelated uveitis. We therefore present the first reported case of sterile postoperative endophthalmitis following HOYA IOL insertion.
